Remove Big Data Remove Compliance Remove Development Remove Medicine
article thumbnail

Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research

ACRP blog

If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.

article thumbnail

EMA urges “human-centric approach” to AI in drug discovery

Drug Discovery World

The EMA has published a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines. The use of AI is rapidly developing in society and as regulators we see more and more applications in the field of medicines. “The

Drugs 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Technology Trends and Collaborations are Ushering in a New Era of ‘Pharmaceutical Intelligence’

ACRP blog

AI is increasingly important in drug discovery and development as well as clinical trials, operations, pharmacovigilance, and many other areas.” This will also allow companies to utilize advanced computational models to find better treatments more quickly while also reducing costs associated with drug development.

article thumbnail

Medical Informatics: a bridge between two worlds

pharmaphorum

The webinar will also cover: How the necessary routine and research data can be collected in registries in a further processable form by patients and healthcare professionals. Optimising and exploiting data for use in rare disease-specific research and studies. About the panel.

Genome 55
article thumbnail

Medical Informatics and Rare Disease: a bridge between two worlds

pharmaphorum

And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. Data privacy and protection, patient voice. Navigating rare disease research and treatment.

Genome 99
article thumbnail

Digital biomarkers in pharma: Q&A with Medidata’s Mark Matson 

Drug Discovery World

Having these new data leads to greater understanding and enables precision medicine. . Once collected, there are data analysis considerations surrounding the large amount of data and the connection to other data sources, such as EDC and eCOA data. Why are digital biomarkers important in clinical trials?